Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms?

PACE - Pacing and Clinical Electrophysiology

Volumn 21, Issue 10, 1998, Pages 1901-1917

  Murakawa, Yuji ^a   Yamashita, Takeshi ^a   Kanese, Yukihiro ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiarrhythmic drugs; Defibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; LIDOCAINE; MEXILETINE; NIFEKALANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEFIBRILLATION; DOG; DRUG EFFECT; HEART ELECTROPHYSIOLOGY; NONHUMAN; SHOCK WAVE; TREATMENT OUTCOME; WAVEFORM;

EID: 0031682608     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1998.tb00009.x     Document Type: Article

References (40)

1. Naccarelli GV, Dougherty AH, Wolbrette D. Antiarrhythmic drug-implantable cardioverter defibrillator interactions. In DP Zipes, J Jalife (eds.): Cardiac Electrophysiology. From Cell to Bedside. Philadelphia, WB Saunders Company, 1995, pp. 1426-1433.
2. Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation 1989; 79:1106-1117.
3. Dorian P, Fain E, Davy JM, et al. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy. J Am Coll Cardiol 1986; 8: 327-332.
4. Fain ES, Dorian R, Davy JK, et al. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986; 73: 1334-1341.
5. Kerber PE, Pandian NG, Jensen SR, et al. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: Experimental studies. J Am Coll Cardiol 1986; 7:397-405.
6. Frame LH, Sheldon JH. Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes. J Am Coll Cardiol 1988; 12:746-752.
7. Hernandez R, Mann DE, Breckinridge S, et al. Effects of flecainide on defibrillation thresholds in the anesthetized dog. J Am Coll Cardiol 1989; 14:777-781.
8. Marinchak RA, Friehling TD, Kline RA, et al. Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the literature. PACE 1988; 11:7-12.
9. Murakawa Y, Inoue H, Kuo TT, et al. Prolongation of intraventricular conduction time associated with fatal impairment of defibrillation efficacy during treatment with class I antiarrhythmic agents. J Cardiovasc Pharmacol 1995; 25:194-199.
10. Echt DS, Gremillion ST, Lee JT, et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 1994; 5:752-760.
11. Peters W, Gang ES, Okazaki H, et al. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Am Heart J 1991; 122:1355-1360.
12. Dorian P, Wang M, David I, et al. Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model. Circulation 1991; 83:614-621.
13. Dorian P, Newman D, Harris L, et al. Sotalol in patients with implanted automatic defibrillators: Effects on defibrillation and comparison with amiodarone. Can J Cardiol 1994; 10:193-200.
14. Szabo TS, Jones DL, Klein GJ. Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs. J Cardiovasc Pharmacol 1988; 12:377-383.
15. Natale A, Montenero AS, Bombardieri G, et al. Effects of acute and prolonged administration of propafenone on internal defibrillation in the pig. Am Heart J 1992; 214:104-109.
16. Montenero AS, Bombardieri G, Barilaro C, et al. Intravenous propafenone reduces energy requirements for defibrillation in pigs. Cardiologia 1990; 35:291-294.
17. Bardy GH, Ivey TD, Allen MD, et al. A prospective randomized evaluation of biphasic versus monophasic waveform pulses on defibrillation efficacy in humans. J Am Coll Cardiol 1989; 14:728-733.
18. Chang MS, Inoue H, Kallok MJ, et al. Double and triple shocks reduce ventricular defibrillation threshold in dogs with and without myocardial infarction. J Am Coll Cardiol 1986; 8:1393-1405.
19. Dixon EG, Tang AS, Wolf PD, et al. Improved defibrillation thresholds with large contoured epicardial electrodes and biphasic waveforms. Circulation 1987; 76:1176-1184.
20. Tang AS, Yabe S, Wharton JM, et al. Ventricular defibrillation using biphasic waveforms: The importance of phasic duration. J Am Coll Cardiol 1989; 13:207-214.
21. Blanchard SM, Ideker RE. Mechanisms of electrical defibrillation: Impact of new experimental defibrillation waveforms. Am Heart J 1994; 127: 970-977.
22. Walcott GP, Walcott KT, Knisley SB, et al. Mechanisms of defibrillation for monophasic and biphasic waveforms. PACE 1994; 117:478-498.
23. Ujhelyi MR, Schur M, Frede T, et al. Differential effects of lidocaine on defibrillation threshold with monophasic versus biphasic waveforms. Circulation 1995; 92:1644-1650.
24. Babbs CF. Effect of pentobarbital anesthesia on ventricular defibrillation threshold in dogs. Am Heart J 1978; 95:331-337.
25. Kiehn J, Wible B, Lacerda AE, et al. Mapping of a cloned human inward rectifier potassium channel by dofetilide. Mol Pharmacol 1996; 50:380-387.
26. Rasmussen HS, Allen MJ, Blackburn KJ, et al. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20(Suppl. 2):S96-S105.
27. Nakaya H, Tohse N, Takeda Y, et al. Effect of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109:157-163.
28. Sato R, Koumi S, Hisatome I, et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1995; 274:469-474.
29. Epstein AE, Ellenbogen KA, Kirk KA, et al. Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study. Circulation 1992; 86:1206-1216.
30. Jung W, Manz M, Pizzuli L, et al. Effect of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992; 70:1023-1027.
31. Kodama I, Shibata N, Sakuma I, et al. After effects of high-intensity DC stimulation on the electromechanical performance of ventricular muscle. Am J Physiol 1994; 267:H248-H258.
32. Murakawa Y, Yamashita T, Ajiki K, et al. Effects of class III antiarrhythmic drug and biphasic shocks on the postdefibrillation refractory period of relatively refractory myocardium. J Cardiovasc Electrophysiol 1996; 7:603-611.
33. Nelson SD, Lenhart MB, Saffarin A. The influence of sodium channel blockade on the defibrillation energy requirement of biphasic versus monophasic shocks. PACE 1996; 19:1568-1573.
34. Zhou X, Daubert JP, Wolf PD, et al. Epicardial mapping of ventricular defibrillation with monophasic and biphasic shocks in dogs. Circ Res 1993; 72:145-160.
35. Yabe S, Smith WM, Daubert JP, et al. Conduction disturbances caused by high current density electric fields. Circ Res 1990; 66:1190-1203.
36. Costard-Jaeckle A, Liem LB, Franz MR. Frequency-dependent effect of quinidine, mexiletine, and their combination on postrepolarization refractoriness in vivo. J Cardiovasc Pharmacol 1989; 14: 810-817.
37. Nakaya Y, Nii H, Nomura M, et al. Effects of lidocaine and quinidine on post-repolarization refractoriness after the basic and premature action potentials: consideration of aim of antiarrhythmic drug therapy. Am Heart J 1989; 118:907-912.
38. Kerber RE, Pandian NG, Hoyt R, et al. Effect of ischemia, hypertrophy, hypoxia, acidosis and alkalosis on canine defibrillation. Am J Physiol 1983; 244:H825-H831.
39. Babbs CF, Whistler SJ, Yim GK, et al. Dependence of defibrillation threshold upon extracellular/intracellular K concentration. J Electrocardiol 1980; 13:73-78.
40. Feeser SA, Tang ASL, Kavanagh KM, et al. Strength-duration and probability of success curves for defibrillation with biphasic waveform. Circulation 1990; 82:2128-2141.